SCI
DFTX icon

Stableford Capital II’s Definium Therapeutics DFTX Stock Holding History

Stableford Capital II’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$988K Sell
25,951
-1,190
-4% -$50.1K 0.34% 88
2026
Q2 		$1.28M Buy
+27,141
New +$671K 0.44% 56

Other funds holding DFTX

FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
BWM
Bullock Wealth Management Bloomington, Indiana $241M AUM 23.31% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.66B AUM 13.15% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Stableford Capital II's DFTX Position: Q3 2026 in Review

Stableford Capital II reduced its Definium Therapeutics (DFTX) stake by 4.4% in Q3 2026, selling an estimated $50.1K and leaving 25,951 shares worth $988K. The position accounts for 0.34% of the portfolio, ranked #88.

Stableford Capital II first reported a position in DFTX in Q2 2026 and has held it in 2 quarters since. The position peaked at $1.28M in Q2 2026. 8 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • Stableford Capital II held 25,951 shares of Definium Therapeutics worth $988K as of Q3 2026.
  • Stableford Capital II sold 1,190 Definium Therapeutics shares in Q3 2026, an estimated $50.1K.
  • Definium Therapeutics made up 0.34% of Stableford Capital II's portfolio in Q3 2026, its #88 holding.
  • Stableford Capital II first reported a position in Definium Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Stableford Capital II's Definium Therapeutics position peaked at $1.28M in Q2 2026.
  • 8 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Stableford Capital II's 13F filing for Q3 2026, filed 9 Oct 2026.